
Sara López-Tarruella
@sltc21
Medicine, Oncology and Research. Science is founded on uncertainty...📚🎧🐾🏐@geicam @info_Iisgm @ucm #cancerdemama #TNBC #MBC #bcsm
ID: 2342024225
13-02-2014 20:55:36
1,1K Tweet
730 Followers
904 Following

The #AURORA Data Analysis Committee is in Florence for a “datathon”! Over the next 2 days, PIs, bioinformaticians, clinicians, and BIG HQ are working together on analyses to advance a new AURORA manuscript. Philippe Aftimos, MD Angel Guerrero-Zotano, MD,PhD Gabriele Zoppoli Elisa Agostinetto Carmela Caballero


Nos dan la bienvenida a esta #JornadaCáncerDeMamaHereditario las coordinadoras del encuentro ➡️ la Dra. Judith Balmaña, del Hospital Universitario Vall d'Hebron, en Barcelona; la Dra. Raquel Andrés (Raquel Andrés), del Hospital Universitario Lozano Blesa de Zaragoza; y la Dra.





We’re already at #ESMOBreast25 👏🏼! 📍 As we shared a few days ago, we are in the city of Munich, where we have just presented the results of two important studies. Led by Dr. José Alejandro Pérez-Fidalgo, an oncologist affiliated with GEICAM - Cáncer de mama 🩺, we have recently presented the


🔬 More contributions from GEICAM at #ESMOBreast25 🔬 The second study that has just been presented is ST-2023-03 ShareView, defended by Dr. Begoña Bermejo de las Heras 🩺, an oncologist associated with GEICAM - Cáncer de mama. This analysis uses a novel statistical methodology called



🟣🙌🏼 Hello from #ASCO25 🙌🏼🟣 We are excited to present three GEICAM - Cáncer de mama studies that reaffirm the importance of molecular and immunological #biomarkers in the clinical management of breast cancer. The analysis from the #CIBOMA trial, presented by Dr. Federico Rojo, Dr. Ángel


🟣 New immunological insights into breast cancer during #pregnancy and breastfeeding. GEICAM - Cáncer de mama has also presented new data from the #EMBARCAM study at #ASCO25 🔬 This molecular and immunological analysis, developed in collaboration with IMIBIC by Dr. Juan de la Haba (Juan de la Haba),


🟣 Biomarkers in metastatic #breastcancer More from #ASCO2025 🩺 Dr. Ángel Guerrero (Angel Guerrero-Zotano, MD,PhD) and Dr. Miguel Martín present an important finding in the treatment of the most common type of #metastatic breast cancer: hormone receptor-positive and HER2-negative (HR+/HER2-).


🧪🤖 "GEICAM está explorando activamente el potencial de la #InteligenciaArtificial en la investigación y el abordaje del cáncer de mama". 🗨️ El presidente de GEICAM - Cáncer de mama , el doctor Ander Urruticoechea, habló sobre #IA, sobre registros pioneros en España -como el de #cáncerdemama


Ya en sesión de tarde en la @uimp hablando de medicina personalizada para mejorar los resultados de salud y la integración de la IA. Participan: Francisco Ayala, miembro de GEICAM - Cáncer de mama Senén Barro Ameneiro Yaki Hernández (Saray) Modera: Teresa Barros, de adi sulaj #cancerdemama


¿Cómo de importante es la atención primaria en el cáncer de mama? Con Carmen Hinojo, representante de SEOM, Roberto Bernal de semFYC, María Jesús Riera de ALBA MENORCA y Catiana Martinez de Asociacion AMIGA. Modera: Asociación S. Águeda UIMP #cancerDeMama


Accede al Dossier completo 👇🏻 seom.org/publicaciones/… SOLTI #cancerresearch GEICAM - Cáncer de mama Grupo Español de Tratamiento de Tumores Digestivos TTCC-GrupoTratamiento Tumores Cabeza y Cuello GEICO-Spanish Gynaecological Cancer Research Group Grupo Español de Cáncer de Pulmón SOGUG GUARD Consortium GEIS GEINO gética GECOD ICAPEM Grupo GETNE GEM GOTEL - Grupo Linfomas Grupo GETTHI @GrupoGemcad & GrupoGerminal




Phase II SPOTLIGHT-203 trial results from Iván Márquez Rodas 🇪🇦: BO-112 + pembrolizumab shows 25% ORR in patients w/ anti–PD-1–resistant melanoma. Median OS not reached at 24 mo. Grade ≥3 AEs in 38%. Full study: ascopost.com/news/july-2025… #Oncology #Melanoma #Immunotherapy


📢 New open-access article in npj Breast Cancer, co-authored by BIG’s leadership, explores the challenges of academic clinical trials and how to ensure their future impact. 📄 Read more: nature.com/articles/s4152… #BIGAgainstBreastCancer #breastcancer #research npj Journals
